New eye injection aims to slow vision loss in rare disease
NCT ID NCT07282457
First seen Jan 04, 2026 · Last updated Jun 11, 2026 · Updated 28 times
Summary
This early-stage trial tests a single injection of ZM-02 in 21 people aged 6 to 60 with advanced retinitis pigmentosa, a genetic eye disease that causes vision loss. The study checks if the treatment is safe and whether it can improve vision and quality of life compared to a sham procedure. It is not a cure, but aims to control the disease and preserve remaining sight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA (RP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.